卒中后原发性醛固酮增多症检测不足:多中心队列研究
这项在澳大利亚维多利亚州两家三级医院开展的多中心回顾性队列研究,纳入2019年1月至2020年1月因卒中或短暂性脑缺血发作入院的400例患者,评估原发性醛固酮增多症检测频率。结果显示,30%(120例)存在检测临床指征,但仅2%(8例)接受了检测。作者认为这是卒中照护路径中识别可治疗高血压病因的遗漏机会。
要点
- 卒中或TIA患者中30%有原发性醛固酮增多症检测指征,但仅2%被检测。
- 原发性醛固酮增多症是可干预的心脑血管风险因素,却严重诊断不足。
- 在卒中照护路径中常规筛查可能通过靶向治疗改善长期结局。
核心结论
- 卒中或短暂性脑缺血发作患者中原发性醛固酮增多症检测严重不足,提示存在识别可治疗高血压病因的遗漏机会。
研究设计与样本
- 多中心回顾性队列研究,纳入2019年1月至2020年1月在澳大利亚维多利亚州两家大型三级医院因卒中或短暂性脑缺血发作入院的400例患者。
- 从病历中收集血压、降压药物使用、血清钾和肾上腺影像等数据。
主要发现
- 400例患者平均年龄73.9±13.4岁,女性占42.1%。
- 30%(n=120)存在原发性醛固酮增多症检测的临床指征,但仅2%(n=8)接受了检测。
临床怎么用
- 在卒中或短暂性脑缺血发作患者的照护路径中,应考虑对具备临床指征者常规筛查原发性醛固酮增多症。
- 通过靶向药物或手术干预可降低血压并减轻心血管风险,可能改善长期结局。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Primary aldosteronism, the most common endocrine cause of hypertension, is associated with an increased risk of stroke compared with essential hypertension. Targeted treatment with mineralocorticoid receptor antagonists, or surgical resection of an aldosterone-producing adrenal adenoma, can effectively reduce blood pressure and mitigate cardiovascular risk. However, despite being a highly modifiable cardiovascular risk factor, primary aldosteronism is grossly underdiagnosed, even in high-risk populations. METHODS: We conducted a multicenter retrospective cohort study to assess the frequency of primary aldosteronism testing among patients admitted between January 2019 to January 2020 with stroke or transient ischemic attack. Data, including blood pressure, antihypertensive medication use, serum potassium, and adrenal imaging, were collected from the medical records of patients admitted for stroke or transient ischemic attack at 2 large tertiary hospitals in Victoria, Australia. RESULTS: Among 400 patients (mean age, 73.9±13.4 years; 42.1% female), 30% (n=120) had a clinical indication for primary aldosteronism testing, yet only 2% (n=8) were tested. CONCLUSIONS: These findings highlight a missed opportunity to identify a treatable cause of hypertension in patients at high risk of recurrent cerebrovascular events. Routine testing for primary aldosteronism in stroke care pathways may improve long-term outcomes through targeted intervention.
引用
- McCarthy J, Widjaja J, Gao FM, et al. Testing for Primary Aldosteronism Underutilized Following Stroke: A Multicenter Cohort Study. Stroke. 2025. PMID: 41250988. doi:10.1161/STROKEAHA.125.052691
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。